Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 10Urinary Bladder Neoplasms 7Prostatic Neoplasms 6Breast Neoplasms 4Pancreatic Neoplasms 3Neoplasms 3Neoplasm Metastasis 3Lung Neoplasms 3Carcinoma, Transitional Cell 3Uterine Cervical Neoplasms 2Urethral Neoplasms 2Ureteral Neoplasms 2Thyroid Neoplasms 2Sarcoma 2Recurrence 2Ovarian Neoplasms 2Multiple Myeloma 2Melanoma 2Hematologic Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Urologic Neoplasms 1Thrombocytosis 1Stroke 1Stomach Neoplasms 1Soft Tissue Neoplasms 1Renal Pelvis and Ureter Urothelial Carcinoma 1Rectal Neoplasms 1Pulmonary Disease, Chronic Obstructive 1

Interventions

Nutrition Assessment 2tocilizumab 1Tirzepatide 1Testosterone 1Standard of Care 1Specimen Handling 1Resistance Training 1Practice Guidelines as Topic 1Pioglitazone 1Palliative Care 1Metformin 1Lysine Acetyltransferase 5 1Immunoglobulin G 1Gonadotropin-Releasing Hormone 1Exercise 1Disulfides 1Diet, Carbohydrate-Restricted 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Diabetes Mellitus × Disulfides × Genitourinary × Clear all
NCT04361552 2020-06-18

Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)

Emory University

Phase 3 Withdrawn
Genitourinary

COVID-19, Coronary Artery Disease, Diabetes Mellitus, Kidney Failure, Chronic, Neoplasms, Stroke, Pulmonary Disease, Chronic Obstructive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡